尤瑞克林治疗脑梗死疗效观察

Clinical observation on the efficacy of urinary kallidinogenase in the treatment of patients with acute cerebral infarction

目的观察使用尤瑞克林治疗急性脑梗死的远期疗效。方法入选急性脑梗死患者120例,分为治疗组80例及对照组40例;两组均予以相同剂量的阿司匹林,治疗组加用尤瑞克林0.15 PNA单位加入生理盐水100mL,静滴,两组均2周为1疗程。治疗前和尤瑞克林疗程结束后2周、12周分别测定神经功能缺损(NDS)评分,12周时评定临床疗效。结果与对照组对比,尤瑞克林组治疗2周和12周的NDS评分改善明显,尤瑞克林组治疗12周后总有效率90.00%,对照组77.5%,差异有统计学意义(P<0.05)。结论尤瑞克林能显著改善急性脑梗死的神经功能缺损,提高疗效,安全性高,值得临床推广使用。

Objective To observe the efficacy of urinary kallidinogenase in treatment of patients with acute cerebral infarction.Methods There 120 patients with acute cerebral infarction were selected and divided into treatment group consisted of 80 cases and treated with aspirin and conventional therapy plus urinary kallidinogenase and control group consisted of 40 cases and treated only with aspirin and conventional therapy.NDS scores were measured before treatment and 2 weeks after treatment and 12 weeks.The clinical efficacy was evaluated 12 weeks after treatment.Results In comparison with the control group,the NDS scores in the treatment group improved significantly 2 weeks,12 weeks after treatment,showing statistically significant difference（P0.05）.The total effective rate of treatment group 12 weeks after treatment was 90.00% and 77.5% in the control group,showing significant difference（P0.05）.Conclusion Urinary kallidinogenase is effective and safe for treatment of patients with acute cerebral infarction.